Project Grant HT94252410123
Award Date
2/15/24
Completion Date
2/14/27
Dollars Obligated
$989K
Federal Agency
Defense Health Agency
Awardee
Universitat Bern (MX7JPQLVM5V5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Switzerland
Similar Awards
The Department of the Army Medical Command awarded a $438,916 project grant to Universitat Bern in Switzerland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2026 to target PARP inhibitor resistance. Through this funding, Universitat Bern researchers will investigate medical solutions for targeting resistance to poly (ADP-ribose) polymerase inhibitors, an area of focus under the Military Medical...
This federal Project Grant award, valued at $548,133.00 and awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at the University of Basel in Switzerland focused on "Neuronal Regulation of Antitumor Immunity". The award, which began on September 15, 2024 and is scheduled for completion by September 14, 2027, aims to conduct advanced biomedical research investigating the role of neuronal processes in...
This federal Project Grant award of $219,568.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Universitat Bern to investigate the role of intestinal secreted microRNAs in regulating the gut microflora and their impact on inflammatory bowel disease. The research aims to improve understanding of the underlying mechanisms of this condition, which is of relevance to military health. The award has a performance...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
This Project Grant award for $366,000.00, awarded on Sep 30, 2024 by the Defense Health Agency, supports research conducted by The Geneva Foundation to identify functional structural variants that influence therapy outcomes for human castration-resistant prostate cancer. The award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a broad range of biomedical research initiatives to improve health outcomes for military service members,...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
The University of California, San Diego (UCSD) was awarded a $1,218,012 Project Grant from the Defense Health Agency on September 30, 2023 under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "GERMLINE INFLUENCE ON PROSTATE CANCER METASTASIS AND TREATMENT RESPONSE." The research aims to transform health care for Service Members and the American public by investigating medical solutions for the battlefield through innovative and impactful...
This federal Project Grant award of $1,518,817.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding research conducted by Weill Medical College of Cornell University to characterize the role of 3'-UTR biology as a mechanism of therapy response in high-risk prostate cancer. The research aims to advance the understanding of how specific genetic factors impact treatment outcomes for this challenging form of cancer, with...